Articles tagged with Diabetic Retinopathy
A four-year clinical trial from the DRCR Retina Network found that early anti-VEGF injections slowed diabetic retinopathy progression, but did not improve vision at two years. Standard treatment remained effective in preventing further vision loss.
Researchers at Johns Hopkins Medicine used autonomous AI to detect pediatric diabetic retinopathy in a study of 310 patients. The AI tool achieved high sensitivity, specificity, and diagnosability rates, leading to improved screening adherence and early diagnosis.
Researchers tested seven AI screening algorithms against expert ophthalmologists and found that most perform poorly in real-world settings, highlighting the need for proper image quality and training data. Only one algorithm matched human screener performance.
A new 30-year study found that public health services worldwide have failed to meet targets for reducing avoidable sight loss, with cataract and uncorrected refractive error being major contributors. The number of cases of blindness and severe vision impairment is expected to rise dramatically by 2050.
A new study found that public health services are failing to meet targets to reduce avoidable sight loss, with a significant increase in cases despite a decrease in prevalence. Cataract is the leading cause of blindness, accounting for 15 million people, and treatable by surgery.
People with diabetes and eye disease are at a higher risk of requiring intubation when hospitalized with COVID-19. Diabetic retinopathy was associated with a five-fold increased risk for intubation in patients hospitalized with severe COVID-19.
Researchers developed a novel deep learning method that requires less annotated image data to screen for diabetic retinopathy, achieving the same diagnostic performance as human experts. The method enables clinics to automate screenings and reduce referrals to specialized eye care centers.
A study found a high prevalence of type 2 diabetes (60.5%) among the Xavante population, with severe cases threatening sight. The researchers used a portable retinograph to detect diabetic retinopathy and found 16 cases, highlighting the need for screening in remote communities.
A new study published in Science sheds light on a cellular process in diabetic retinopathy, which could lead to the development of a treatment for this serious complication of diabetes. The research reveals that blood vessels apply molecular brakes to stop abnormal vascular proliferation.
A new study found that ideal cardiovascular health is associated with lower odds for developing ocular diseases, particularly diabetic retinopathy. Practicing healthy lifestyles such as regular physical activity, healthy diet, and maintaining normal weight may also contribute to good eye health.
A new study published in the American Journal of Pathology reports that a single dose of visual chromophore 9-cis-retinal improves visual function in diabetic mice by reducing oxidative stress and cell death. This treatment may represent a potential therapy for early diabetic retinopathy.
Researchers at Pohang University of Science & Technology developed smart contact lenses that can detect diabetes and treat diabetic retinopathy by controlling insulin secretion with electrical signals. The lenses verified accurate glucose level detection in tears of diabetic rabbits.
Researchers found that lixisenatide significantly reduced neuroinflammation in the retina and optic nerve head of mice with early type 2 diabetes. The study suggests a novel therapeutic strategy for preventing visual deterioration in diabetic retinopathy before its clinical manifestation.
Researchers followed patients with diabetes who developed diabetic retinopathy and found a 60% higher risk of stroke among those with damaged eye vessels. Patients with diabetic retinopathy should receive aggressive medical management to reduce stroke risk.
A WVU project uses the Intelligent Retinal Imaging System to detect diabetic retinopathy in West Virginians, reducing risk of severe vision loss by 90%. Over 5,400 patients have been screened, with 21% showing evidence of retinopathy.
Researchers developed a smart photonic contact lens that measures glucose concentration in conjunctival blood vessels, enabling diabetic diagnosis. The device also shows promise for treating diabetic retinopathy by reducing angiogenesis and verifying clinical feasibility.
A new AI screening system has been shown to accurately detect diabetic retinopathy in 95.5% of cases, making real-time screening possible for primary care practices and diabetes centers. The EyeArt system can provide a reading in 60 seconds and does not require the input of an expert ophthalmologist.
Researchers found that montelukast can disrupt inflammatory signaling in diabetic retinopathy, reducing small blood vessel and nerve damage. The study offers an early approach to treat type 1 diabetes and suggests a potential new treatment for the disease.
Researchers analyzed samples from over 1,000 type 1 diabetes patients for 50 years or longer and found a protective protein called RBP3. Injecting RBP3 into rodents blocked diabetic retinopathy without severe side effects.
Phelcom's Eyer uses a portable optical device connected to a smartphone to capture images of the retina for remote diagnosis. The app sends images over the internet to Eyer Cloud, which stores and manages patient files. With an accuracy rate of around 80%, the system has the potential to examine 50,000 patients next year.
Researchers at Michigan Medicine developed a smartphone-based tool that uses artificial intelligence to analyze retinal images and detect diabetic retinopathy. The device, called RetinaScope, achieved high sensitivity and specificity rates in a study, outperforming human graders in detecting the condition.
Researchers have found and tested compounds from a group of plants that could be used to treat proliferative diabetic retinopathy and other degenerative eye diseases. The study suggests that these natural compounds may provide a new approach to treating blindness caused by diabetes, offering hope for future treatments.
A new study published in Ophthalmology shows that AI can assist physicians in accurately diagnosing diabetic retinopathy, a potentially blinding eye disease. The researchers developed two types of assistance to help physicians read the algorithm's predictions, which improved diagnostic accuracy and confidence.
UVA is expanding its telehealth capacity to help patients manage chronic conditions like diabetes, prediabetes, and heart disease. The initiative includes remote monitoring, screenings, home rehabilitation programs, and training for healthcare providers.
Researchers developed an image-processing algorithm that can automatically detect fluid on the retina with high accuracy. Early diagnosis is crucial as diabetic retinopathy can cause irreversible vision loss if left untreated.
The TGen-UNM consortium has been awarded a $2.8 million grant to investigate the genetic causes of diabetic retinopathy and develop precision medicine-based treatments. The study aims to identify new biomarkers and therapeutic targets to prevent the progression of the disease.
A clinical trial showed AI detected diabetic retinopathy as accurately as expert clinicians, with a sensitivity of 87% and specificity of 90%. Early detection may prevent vision loss, which affects 24,000 Americans annually.
A team of researchers has created a mouse model exhibiting diabetic retinopathy symptoms, paving the way for future translational research studies. The study also reveals that the NLRP3 inflammasome plays a key role in the development of diabetic retinopathy.
A team of researchers has developed a glowing contact lens that reduces the retina's oxygen demands at night, potentially preventing diabetic retinopathy. Early testing shows promising results, with rod cell activity reduced by up to 90 percent when worn in the dark.
A Michigan State University study found unusual lipids in the retina's blood vessels, which may prevent diabetic retinopathy by strengthening the blood-retinal barrier. The discovery could lead to new treatments involving injections or eye drops.
Research at the University of Helsinki found that diabetic retinopathy is characterized by the growth of new lymphatic vessels in the eye. The study suggests that targeting both lymphangiogenesis and angiogenesis may lead to novel treatments for ischemia and inflammation-associated retinal diseases.
A new study found that automated reminder calls improved diabetic eye disease screening rates among low-income minority patients, particularly African Americans. The study showed a significant increase in retinal screenings after receiving robocall reminders, with show rates of 51.6% for African Americans and 61% for Latinos.
A new study published in the American Academy of Ophthalmology journal demonstrates an AI program that detects diabetic eye disease with improved accuracy by incorporating expert feedback from retina specialists. The research provides a groundwork for developing automated systems for screening patients at risk for diabetic retinopathy.
A deep learning computing system developed to classify retinal images can detect diabetic retinopathy, glaucoma, and age-related macular degeneration with high accuracy. The study used 494,661 retinal images from diverse patient populations.
A new smartphone app has shown comparable results to in-office vision testing for patients with age-related macular degeneration and diabetic retinopathy. The Checkup app encourages patients to take an active role in their care, sending reminders and storing test results securely.
The Endocrine Society examines how diabetes damages microvascular system, causing complications such as diabetic retinopathy and kidney disease. Maintaining tight control over blood sugar levels may help reduce risk of complications, but also poses risk of hypoglycemia and cardiovascular issues.
The study identified a protein called ARF6, which plays a key role in the development of diabetic retinopathy. When inhibited with compound NAV-2729, vessel leakage and blood vessel overgrowth were significantly reduced in diabetic mice.
Researchers at Monash University have discovered the presence of regulatory T cells in the retina, a potential target for treating retinopathy of prematurity. The study's findings suggest that boosting these cells may repair damaged blood vessels in the retina, reducing ROP risk.
A study published in Diabetologia found approximately 1.8 million US adults aged 40+ with diabetes, CKD, and diabetic retinopathy, indicating a significant risk of CKD progression and death. The presence of DR is a reliable screening tool for identifying individuals at high risk.
A Japanese study questioned the benefit of treat-to-target intensive statin therapy in patients with diabetic retinopathy, finding no significant reduction in cardiovascular events. However, subanalysis showed that reaching an LDL cholesterol target of less than 70 mg/dL significantly reduced primary endpoint incidence.
The accumulation of advanced glycosylation end-products (AGEs) in the retina triggers oxidative stress, impairing defense mechanisms and leading to neuronal dysfunction. New therapeutic approaches targeting neurotrophic factors may offer potential for regenerative effects on retinal ganglion cells.
Researchers found that pericyte loss worsens retinal environment and function in mouse models of diabetic retinopathy. Pericytes regulate a molecular pathway associated with vascular stabilization, and their absence accelerates disease progression.
A new article published by JAMA Internal Medicine describes the successful implementation of a large-scale primary care-based teleretinal diabetic retinopathy screening program in Los Angeles County. The program eliminated the need for over 14,000 specialty visits and reduced wait times for screening by 89.2%.
A study found that only 65% of youths with type 1 diabetes and 42% of those with type 2 diabetes had undergone an eye examination by six years after initial diagnosis. Groups at reduced likelihood of screening include racial minorities and economically disadvantaged youth.
Researchers identified secretogranin III as a potential therapeutic target for preventing diabetic retinopathy and retinopathy of prematurity. Inhibiting this protein may reduce vision loss in both conditions.
Researchers at Case Western Reserve University School of Medicine have identified the CD40 receptor on Mueller cells as the primary driver of diabetic retinopathy. The study reveals that this receptor initiates inflammation in the retina, leading to vision impairment.
Researchers found that a two-drug combination provided better protection against diabetes-related vision loss than a single drug in rat models. The treatment reduced capillary loss by 68% and decreased inflammation, slowing the progression of diabetic retinopathy.
A new RNAi treatment has shown significant improvement in mouse models of acute uveitis and chronic diabetic inflammation without apparent side effects. The therapy targets the receptor-associated prorenin system, involved in uveitis pathogenesis.
Researchers found that a slight increase in transforming growth factor beta (TGF-β) protects retinal blood vessels from damage in early diabetic eye disease. The study suggests that inhibiting TGF-β may accelerate the disease, while increasing its signaling could prevent or delay diabetic retinopathy.
Scientists have discovered that a man-made version of soluble gp130, or sgp130, can inhibit inflammation in the eye and prevent retinal destruction associated with diabetes. The new molecule, called sgp130-Fc, has been shown to reduce inflammation and improve vision in mouse models of diabetic retinopathy.
A study published in JAMA evaluated an algorithm using deep machine learning to detect referable diabetic retinopathy, achieving high sensitivities and specificities. The algorithm was validated on two separate data sets, showing promise for increasing efficiency and coverage of screening programs.
A study by Drs. Sapieha and Mallette reveals a program of accelerated aging in the retina, leading to cellular senescence and production of factors that contribute to blinding disease. Interfering with this process using novel drugs improves blood vessel regeneration and reduces retinal damage.
A new study from LA BioMed found that lower-income minority patients and healthcare providers have markedly divergent perceptions of the barriers to diabetic retinopathy screening. Patients reported financial burden and depression as major obstacles, while providers deemed other factors more significant.
Researchers found that patients are willing to participate in telemedicine for diabetic retinopathy screening if it is convenient and tailored to their needs. The study suggests that telemedicine could ease the burden on patients who face high costs, lack of access, or difficulty with transportation.
A large-scale study found that consuming at least 500mg of dietary omega-3 fatty acids daily was associated with a 48% reduced risk of developing sight-threatening diabetic retinopathy. The study, published in JAMA Ophthalmology, involved over 3,500 adults with type 2 diabetes and followed them for six years.
A study published in JAMA Ophthalmology found that sedentary behavior is associated with an increased risk of diabetic retinopathy. Participants with diabetes who spent more time sitting had a 16% higher chance of developing mild or worse DR compared to those who were more active.
Researchers have developed a gene delivery system that can be applied as an eye drop, rapidly moving from the surface to the retina and remaining for over eight hours. This method shows promise for treating several eye diseases, including diabetic retinopathy and age-related macular degeneration.
Researchers created a virtual tissue model of diabetes in the eye, predicting how a small protein causes vision loss and blindness. The study aims to develop new treatment methods for diabetic retinopathy, a leading cause of blindness worldwide.
A study found that severe non-proliferative and proliferative diabetic retinopathy stages are associated with increased depressive symptoms in people with diabetes. Moderate or severe vision impairment, but not diabetic macular edema, contributed to the risk of depression.
A follow-up analysis of the ACCORD Trial found that people with type 2 diabetes who intensively controlled their blood sugar level had cut their risk of diabetic retinopathy in half. The study, supported by the National Eye Institute, suggests that well-controlled glycemia has a positive and lasting effect on eye health.